Stifel Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-66,325
| Closed | -$170K | – | 3476 |
|
|
2024
Q2 | $170K | Sell |
66,325
-833
| -1% | -$2.14K | ﹤0.01% | 3138 |
|
|
2024
Q1 | $330K | Buy |
67,158
+48,211
| +254% | +$237K | ﹤0.01% | 2858 |
|
|
2023
Q4 | $167K | Buy |
18,947
+3,991
| +27% | +$35.1K | ﹤0.01% | 3090 |
|
|
2023
Q3 | $172K | Buy |
14,956
+700
| +5% | +$8.03K | ﹤0.01% | 3024 |
|
|
2023
Q2 | $361K | Sell |
14,256
-660
| -4% | -$16.7K | ﹤0.01% | 2726 |
|
|
2023
Q1 | $480K | Sell |
14,916
-2,036
| -12% | -$65.6K | ﹤0.01% | 2534 |
|
|
2022
Q4 | $313K | Sell |
16,952
-4,750
| -22% | -$87.7K | ﹤0.01% | 2734 |
|
|
2022
Q3 | $586K | Buy |
21,702
+4,941
| +29% | +$133K | ﹤0.01% | 2340 |
|
|
2022
Q2 | $232K | Buy |
+16,761
| New | +$232K | ﹤0.01% | 2896 |
|
|
2021
Q4 | – | Sell |
-15,847
| Closed | -$442K | – | 3489 |
|
|
2021
Q3 | $442K | Buy |
15,847
+3,667
| +30% | +$102K | ﹤0.01% | 2647 |
|
|
2021
Q2 | $362K | Buy |
12,180
+84
| +0.7% | +$2.5K | ﹤0.01% | 2772 |
|
|
2021
Q1 | $338K | Sell |
12,096
-1,781
| -13% | -$49.8K | ﹤0.01% | 2717 |
|
|
2020
Q4 | $393K | Buy |
13,877
+2,886
| +26% | +$81.7K | ﹤0.01% | 2460 |
|
|
2020
Q3 | $276K | Sell |
10,991
-2,731
| -20% | -$68.6K | ﹤0.01% | 2457 |
|
|
2020
Q2 | $335K | Buy |
13,722
+102
| +0.7% | +$2.49K | ﹤0.01% | 2283 |
|
|
2020
Q1 | $204K | Sell |
13,620
-5,841
| -30% | -$87.5K | ﹤0.01% | 2432 |
|
|
2019
Q4 | $319K | Sell |
19,461
-4,296
| -18% | -$70.4K | ﹤0.01% | 2502 |
|
|
2019
Q3 | $312K | Buy |
23,757
+1,953
| +9% | +$25.6K | ﹤0.01% | 2425 |
|
|
2019
Q2 | $286K | Sell |
21,804
-6,117
| -22% | -$80.2K | ﹤0.01% | 2529 |
|
|
2019
Q1 | $438K | Buy |
+27,921
| New | +$438K | ﹤0.01% | 2142 |
|